CD86 and neoplasm: In vivo studies revealed that ILC1s indeed inhibited tumor growth and upregulated the percentage of macrophage CD86 expression level, while ILC1-blocking antibodies promoted tumor growth in MC38 tumor-bearing mice and decreased macrophage CD86 expression level.